Biomind Labs Inc.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more
Biomind Labs Inc. (BMNDF) - Total Assets
Latest total assets as of September 2025: $57.66K USD
Based on the latest financial reports, Biomind Labs Inc. (BMNDF) holds total assets worth $57.66K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biomind Labs Inc. - Total Assets Trend (2015–2024)
This chart illustrates how Biomind Labs Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biomind Labs Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Biomind Labs Inc.'s total assets of $57.66K consist of 51.3% current assets and 48.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Biomind Labs Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomind Labs Inc.'s current assets represent 51.3% of total assets in 2024, an increase from 12.9% in 2015.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2024, down from 12.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Biomind Labs Inc. Competitors by Total Assets
Key competitors of Biomind Labs Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Biomind Labs Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Biomind Labs Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Biomind Labs Inc. is currently not profitable relative to its asset base.
Biomind Labs Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.02 | 0.69 |
| Quick Ratio | 0.04 | 0.02 | 0.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.56 Million | $ -1.54 Million | $ -24.22K |
Biomind Labs Inc. - Advanced Valuation Insights
This section examines the relationship between Biomind Labs Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 183.79 |
| Latest Market Cap to Assets Ratio | 247.27 |
| Asset Growth Rate (YoY) | -44.5% |
| Total Assets | $41.16K |
| Market Capitalization | $10.18 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Biomind Labs Inc.'s assets at a significant premium ( 247.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Biomind Labs Inc.'s assets decreased by 44.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biomind Labs Inc. (2015–2024)
The table below shows the annual total assets of Biomind Labs Inc. from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $41.16K | -44.53% |
| 2023-12-31 | $74.20K | -16.69% |
| 2022-12-31 | $89.06K | -96.48% |
| 2021-12-31 | $2.53 Million | +2782.71% |
| 2020-12-31 | $87.69K | -76.34% |
| 2019-12-31 | $370.67K | -76.42% |
| 2018-12-31 | $1.57 Million | -90.92% |
| 2017-12-31 | $17.32 Million | +0.57% |
| 2016-12-31 | $17.22 Million | -0.22% |
| 2015-12-31 | $17.26 Million | -- |